Literature DB >> 24696430

Long-term risk of medical conditions associated with breast cancer treatment.

Deirdre A Hill1, Nora K Horick, Claudine Isaacs, Susan M Domchek, Gail E Tomlinson, Jan T Lowery, Anita Y Kinney, Jonathan S Berg, Karen L Edwards, Patricia G Moorman, Sharon E Plon, Louise C Strong, Argyrois Ziogas, Constance A Griffin, Carol H Kasten, Dianne M Finkelstein.   

Abstract

Early and late effects of cancer treatment are of increasing concern with growing survivor populations, but relevant data are sparse. We sought to determine the prevalence and hazard ratio of such effects in breast cancer cases. Women with invasive breast cancer and women with no cancer history recruited for a cancer research cohort completed a mailed questionnaire at a median of 10 years post-diagnosis or matched reference year (for the women without cancer). Reported medical conditions including lymphedema, osteopenia, osteoporosis, and heart disease (congestive heart failure, myocardial infarction, coronary heart disease) were assessed in relation to breast cancer therapy and time since diagnosis using Cox regression. The proportion of women currently receiving treatment for these conditions was calculated. Study participants included 2,535 women with breast cancer and 2,428 women without cancer (response rates 66.0 % and 50.4 %, respectively) Women with breast cancer had an increased risk of lymphedema (Hazard ratio (HR) 8.6; 95 % confidence interval (CI) 6.3-11.6), osteopenia (HR 2.1; 95 % CI 1.8-2.4), and osteoporosis (HR 1.5; 95 % CI 1.2-1.9) but not heart disease, compared to women without cancer Hazard ratios varied by treatment and time since diagnosis. Overall, 49.3 % of breast cancer cases reported at least one medical condition, and at 10 or more years post-diagnosis, 37.7 % were currently receiving condition-related treatment. Responses from survivors a decade following cancer diagnosis demonstrate substantial treatment-related morbidity, and emphasize the need for continued medical surveillance and follow-up care into the second decade post-diagnosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696430      PMCID: PMC4096572          DOI: 10.1007/s10549-014-2928-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  30 in total

1.  Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials.

Authors:  Stuart D Russell; Kimberly L Blackwell; Julia Lawrence; John E Pippen; Matthew T Roe; Freda Wood; Virginia Paton; Eric Holmgren; Kenneth W Mahaffey
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  Risk factors for lymphedema after breast cancer treatment.

Authors:  Sandra A Norman; A Russell Localio; Michael J Kallan; Anita L Weber; Heather A Simoes Torpey; Sheryl L Potashnik; Linda T Miller; Kevin R Fox; Angela DeMichele; Lawrence J Solin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-26       Impact factor: 4.254

3.  Long-term cardiovascular mortality after radiotherapy for breast cancer.

Authors:  Kim Bouillon; Nadia Haddy; Suzette Delaloge; Jean-Remy Garbay; Jerome-Philippe Garsi; Pauline Brindel; Abdeddahir Mousannif; Monique G Lê; Martine Labbe; Rodrigo Arriagada; Eric Jougla; Jean Chavaudra; Ibrahima Diallo; Carole Rubino; Florent de Vathaire
Journal:  J Am Coll Cardiol       Date:  2011-01-25       Impact factor: 24.094

4.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

Authors:  Robert E Coleman; Linda M Banks; Samia I Girgis; Lucy S Kilburn; Eduard Vrdoljak; John Fox; Simon J Cawthorn; Ashraf Patel; Claire F Snowdon; Emma Hall; Judith M Bliss; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-02       Impact factor: 41.316

Review 5.  Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.

Authors:  Lesley A Smith; Victoria R Cornelius; Christopher J Plummer; Gill Levitt; Mark Verrill; Peter Canney; Alison Jones
Journal:  BMC Cancer       Date:  2010-06-29       Impact factor: 4.430

6.  Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.

Authors:  Paul E Goss; James N Ingle; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Dongsheng Tu
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

7.  Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.

Authors:  Mary C Pinder; Zhigang Duan; James S Goodwin; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2007-07-30       Impact factor: 44.544

8.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.

Authors:  Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

9.  Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

Authors:  Patricia A Ganz; Michael A Hussey; Carol M Moinpour; Joseph M Unger; Laura F Hutchins; Shaker R Dakhil; Jeffrey K Giguere; J Wendall Goodwin; Silvana Martino; Kathy S Albain
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

10.  Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms.

Authors:  Sandra A Norman; A Russell Localio; Sheryl L Potashnik; Heather A Simoes Torpey; Michael J Kallan; Anita L Weber; Linda T Miller; Angela Demichele; Lawrence J Solin
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

View more
  7 in total

1.  Clinical characteristics of patients with cancer referred for outpatient physical therapy.

Authors:  Meryl J Alappattu; Rogelio A Coronado; Derek Lee; Barbara Bour; Steven Z George
Journal:  Phys Ther       Date:  2014-12-11

2.  The use of a patient-reported outcome questionnaire to assess cancer survivorship concerns and psychosocial outcomes among recent survivors.

Authors:  Steven C Palmer; Carrie T Stricker; Angela M DeMichele; Marilyn Schapira; Karen Glanz; Jennifer J Griggs; Linda A Jacobs
Journal:  Support Care Cancer       Date:  2017-02-23       Impact factor: 3.603

3.  Health information needs and preferences in relation to survivorship care plans of long-term cancer survivors in the American Cancer Society's Study of Cancer Survivors-I.

Authors:  Mary Playdon; Leah M Ferrucci; Ruth McCorkle; Kevin D Stein; Rachel Cannady; Tara Sanft; Brenda Cartmel
Journal:  J Cancer Surviv       Date:  2016-01-07       Impact factor: 4.442

4.  Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.

Authors:  Cody Ramin; Betty J May; Richard B S Roden; Mikiaila M Orellana; Brenna C Hogan; Michelle S McCullough; Dana Petry; Deborah K Armstrong; Kala Visvanathan
Journal:  Breast Cancer Res       Date:  2018-11-13       Impact factor: 6.466

5.  Analyses of the association between breast cancer and osteoporosis/fracture history: a cross-sectional study using KoGES HEXA data.

Authors:  Hyo Geun Choi; Yong Joon Suh; Jung Woo Lee; Chan Yang Min; Dae Myoung Yoo; Suk Woo Lee
Journal:  Arch Osteoporos       Date:  2021-06-19       Impact factor: 2.617

6.  Ethnodrama: An Innovative Knowledge Translation Tool in the Management of Lymphedema.

Authors:  Shahid Ahmed; Elizabeth Quinlan; Linda McMullen; Roanne Thomas; Pam Fichtner; Janice Block
Journal:  J Cancer       Date:  2015-07-16       Impact factor: 4.207

7.  Nationwide Analysis of Treatment Patterns for Korean Breast Cancer Survivors Using National Health Insurance Service Data.

Authors:  Il Yong Chung; Jihyoun Lee; Suyeon Park; Jong Won Lee; Hyun Jo Youn; Jung Hwa Hong; Ho Hur
Journal:  J Korean Med Sci       Date:  2018-10-01       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.